within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AA19_Amineptine;

model Amineptine
  extends Pharmacolibrary.Drugs.ATC.N.N06AA19;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N06AA19</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Amineptine is a tricyclic antidepressant (TCA) primarily used in the past for the treatment of major depressive disorder. It is known for its dopaminergic and mild noradrenergic activity with low anticholinergic effects. Amineptine has been withdrawn from the market in most countries due to concerns over hepatotoxicity and abuse potential, and it is no longer approved for use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral dose administration.</p><h4>References</h4><ol><li><p>Lachatre, G, et al., &amp; Nicot, G (1989). Single-dose pharmacokinetics of amineptine and of its main metabolite in healthy young adults. <i>Fundamental &amp; clinical pharmacology</i> 3(1) 19–26. DOI:<a href=\"https://doi.org/10.1111/j.1472-8206.1989.tb00026.x\">10.1111/j.1472-8206.1989.tb00026.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2714729/\">https://pubmed.ncbi.nlm.nih.gov/2714729</a></p></li><li><p>Grislain, L, et al., &amp; Kamoun, A (1990). Metabolism of amineptine in rat, dog and man. <i>European journal of drug metabolism and pharmacokinetics</i> 15(4) 339–345. DOI:<a href=\"https://doi.org/10.1007/BF03190224\">10.1007/BF03190224</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2088771/\">https://pubmed.ncbi.nlm.nih.gov/2088771</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Amineptine;
